<DOC>
	<DOC>NCT02783976</DOC>
	<brief_summary>This study will collect and evaluate information on the safety and efficacy of Sovaldi-based regimens in routine clinical practice in Mexico. The primary objective of this study is to assess the rates of adverse drug reactions (ADRs), serious adverse events (SAEs), and adverse events (AEs) leading to dose modification, drug discontinuation, or withdrawal from the study in adult patients with chronic hepatitis C virus (HCV) infection treated with Sovaldi in routine clinical practice.</brief_summary>
	<brief_title>Sovaldi-based Regimens in Patients in Mexico With Chronic Hepatitis C Virus Infection in Clinical Practice</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis C, Chronic</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<criteria>Key HCVinfected patients living in Mexico Treatment with a Sovaldibased regimen, per the approved prescribing information, as determined by the patient's treating physician Key Concurrent participation in an HCV clinical trial (except trials not testing investigational medicinal products) Patients presenting a risk of not being able to be followed (eg, patients planning to move or leave the country prior to their SVR12 visit) Note: Other protocol defined Inclusion/Exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>